GOREISAN for Heart Failure (GOREISAN-HF) Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1179 participants.

Also called NCT04691700

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,179 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04691700
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04691700. Randomized; no masking; primary purpose treatment. Start 2021-01-19 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
GOREISAN for Heart Failure (GOREISAN-HF) Trial
Acronym
GOREISAN-HF
Condition
Heart Failure
Condition
Edema
Condition
Traditional Japanese Medicine
Condition
Kampo Medicine
Condition
Clinical Trial
Intervention (Drug)
Goreisan
Intervention (Drug)
Standard Treatment
Lead sponsor
Takeshi Morimoto (class: other)

Record details

Record id
cardio:ct-nct04691700
Content hash
fb6a07a419a83265276e77d564898c2d952f01a38f26a0f3a5e5713c0f731d5c